Biotech Blog Archives: October 2003
next page ·
previous page
30 October 2003
The next big thing is…
The next big thing is…
According to the most recent MoneyTree Survey, a report put together by PricewaterhouseCoopers, Thomson Venture Economics and the National Venture Capital Association, which tracks venture capital investments, biotech and medical equipment firms are really the next big thing …
Although overall VC funding in the third quarter dipped 8 percent from the [...]
continue reading... » 0 Comments
30 October 2003
Pharmaceutical Makers Turn To CRM
Pharmaceutical Makers Turn To CRM
After years of blockbuster medications that literally change the way their customers live, drugmakers are facing a period of uncertainty as the cost of developing the next big thing grows and the discovery pipeline shrinks. Many pharmaceutical companies are turning to customer-relationship-management technology as a means to squeeze revenue from existing [...]
continue reading... » 0 Comments
28 October 2003
Fog Begins to Lift with Q3 Biotech Numbers
Fog Begins to Lift with Q3 Biotech Numbers
Certain market indicators for 2003�s third quarter suggest that at least some investors and analysts are anticipating more boom, less doom.
continue reading... » 0 Comments
28 October 2003
India emerges as new drug trial hot spot
India emerges as new drug trial hot spot
Biotech entrepreneurs see Indian clinical trials � which can cut costs by 60 percent � as the difference between success and slow death.
continue reading... » 0 Comments
27 October 2003
Who’s Going To Pay For Global Health?
Who’s Going To Pay For Global Health?
The amazingly swift global response to the SARS outbreak earlier this year demonstrated once and for all that it is possible for countries to join forces and fight epidemics quickly and effectively. So, shouldn’t the same apply to the true pandemics � AIDS, malaria and tuberculosis? Indeed it should [...]
continue reading... » 0 Comments
26 October 2003
Seeking a Prescription for Biogenerics
Seeking a Prescription for Biogenerics
No U.S. laws allow for generic versions of off-patent biotech medicines. Several forces are now working to change that
